Clinical Trials

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03410615 2026-01-14

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

129 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03381183 2025-12-05

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

19 enrolled

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

120 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03019003 2025-09-16

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

13 enrolled 12 charts

Head and Neck Neoplasms

NCT03529422 2025-07-20

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

18 enrolled 10 charts

Phase EARLY_PHASE1 Active not recruiting

Lymphoid Interstitial Pneumonia, Laryngeal Diseases, Mouth Neoplasms

NCT03215095 2025-07-17

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

11 enrolled 6 charts

Thyroid Neoplasms

NCT03635164 2025-06-27

Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

21 enrolled

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04521686 2025-06-27

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

200 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT03618654 2025-05-15

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

Phase EARLY_PHASE1 Completed

38 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03212469 2025-05-08

ABIMMUNE

GastrointestinalHead & NeckThoracic

54 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Lung Neoplasms

NCT03726775 2025-05-07

REWRITe

61 enrolled

Phase EARLY_PHASE1 Terminated

Squamous Cell Carcinoma of Head and Neck

NCT02827838 2025-03-17

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

17 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

NCT03518606 2025-01-15

MOVIE

BreastGenitourinaryGynecologicHead & Neck

126 enrolled

Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT03509012 2025-01-14

CLOVER

Phase 3 Active not recruiting

105 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04116047 2024-07-29

CompARE

785 enrolled

Phase 1/2 Active not recruiting

Oropharyngeal Neoplasms

NCT03784066 2024-07-03

DUTRELASCO

21 enrolled

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03283605 2024-06-28

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

45 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06446570 2024-06-06

Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

18 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03723967 2024-04-22

FRAIL-IMMUNE

104 enrolled

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT03088059 2023-11-03

UPSTREAM

340 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03624231 2023-08-31

DURTRE-RAD

18 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03522584 2023-06-12

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Terminated

6 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck

NCT03737968 2023-03-21

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

48 enrolled

Laryngeal Diseases

NCT02291055 2023-03-20

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Phase 1/2 Terminated

75 enrolled 23 charts

GynecologicHead & Neck

Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04359199 2023-02-10

QUASAR

Unknown

42 enrolled

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

58 enrolled 24 charts

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT04001413 2022-07-29

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Phase 2 Withdrawn

Oropharyngeal Neoplasms

NCT03122496 2022-06-08

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

13 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT03292250 2022-03-29

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

180 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03799744 2022-03-28

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Phase 1 Unknown

20 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT02318277 2022-01-13

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

176 enrolled 25 charts

Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT03829007 2022-01-10

PINCH

33 enrolled

Head and Neck Neoplasms

NCT03450967 2021-08-10

Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC

31 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03673735 2021-05-10

ADHERE

Phase 3 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT03144778 2021-03-18

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

39 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT01938612 2021-03-12

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

GastrointestinalHead & Neck

269 enrolled

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms

NCT02369874 2021-02-10

EAGLE

Phase 3 Completed

736 enrolled 26 charts

Head and Neck Neoplasms, Recurrence

NCT02423863 2020-12-17

Poly-ICLC

DermatologicHead & NeckSarcoma

26 enrolled

Head and Neck Neoplasms, Melanoma, Neoplasms, Sarcoma

NCT04262388 2020-11-17

DOME

Phase 2 Withdrawn

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT02207530 2020-09-29

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

112 enrolled 20 charts

Head and Neck Neoplasms, Recurrence

NCT02319044 2020-09-29

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

267 enrolled 27 charts

Head and Neck Neoplasms, Recurrence

NCT04447612 2020-06-25

Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

118 enrolled

Nasopharyngeal Carcinoma

NCT02882308 2020-02-07

OPHELIA

41 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02997332 2019-01-03

MEDINDUCTION

Phase 1 Unknown

36 enrolled